Peacock Tariff Consulting works with the Twin Cities MedTech ecosystem – Medtronic, Boston Scientific, 3M suppliers, plus ~400 Medical Alley companies. We focus on Section 232 MedTech probe readiness, pharma 25% tariff spillover, MedTech HTS classification, FDA-CBP coordination, and MN FTZ activation.
The Twin Cities MedTech cluster is the most concentrated, most tariff-exposed medical-device cluster in the U.S. Medtronic, Boston Scientific, 3M, and Target supply chain are the named anchors; ~400 Medical Alley companies surround them. The Section 232 MedTech probe could result in new sectoral duties; the existing pharma tariff already affects adjacent goods.
Peacock Tariff Consulting works with Twin Cities MedTech firms across the ecosystem – from large-cap suppliers to mid-market sub-assembly makers. Section 232 readiness, FDA-CBP overlap, and MedTech HTS classification are core areas.
Section 232 MedTech probe – what to model
Section 232 MedTech investigation is in flight; specific scope and rate determination remain pending. For Twin Cities MedTech firms, the prudent approach is scenario modeling – what does duty exposure look like under three or four plausible scope structures, how do supplier shifts compare, where is forward pricing most sensitive.
We build scenario models on a fixed-fee basis. Useful for board-level discussion and for forward-pricing decisions ahead of the probe outcome.
Pharma 25% spillover into MedTech
Section 232 pharmaceutical tariffs effective July 31, 2026 affect branded patented drugs. Adjacent MedTech goods (drug-device combinations, drug delivery devices, certain diagnostic reagents) sit at scope boundaries that may or may not fall within the pharma probe. Classification verification at the boundary is the first step.
Medical-device HTS – FDA-CBP overlap
Medical devices need both FDA admissibility and CBP entry compliance. Devices classified under FDA Class I, II, or III have distinct CBP entry treatments; HTS subheadings interact with FDA filing requirements. For Twin Cities sub-assembly makers ($10M-$100M revenue), classification review across the SKU set regularly identifies recoverable duty.
Medtronic / Boston Scientific Tier 2 suppliers
Tier 2 suppliers serving Medtronic, Boston Scientific, and other Medical Alley anchors face cascading tariff exposure. The Tier 1’s tariff exposure flows through to component pricing. Our Tier 2 engagements: USMCA stress-tests where applicable, Section 232 readiness on imported metallic and electronic components, and IEEPA refund analysis.
MN FTZ activation for medical-device OEMs
FTZ activation around the Twin Cities provides duty deferral and Section 122 avoidance on re-exports. For medical-device OEMs running U.S.-side assembly with imported components, the math typically supports activation at $20M+ annual import volume.
Frequently asked questions
Do you work with mid-market MedTech firms?
Yes – that is our core engagement profile for the Twin Cities. Sub-assembly makers in the $10M-$100M range, plus larger Tier 2 suppliers to Medtronic and Boston Scientific.
Can you model Section 232 MedTech scope scenarios?
Yes. Scenario modeling is a fixed-fee engagement covering plausible scope structures and rate levels. Useful for board-level review and forward pricing.
How does FDA-CBP coordination work?
Medical devices need FDA admissibility (registration, listing, premarket clearance) and CBP entry compliance. Conflicts arise when FDA categorization and HTS classification diverge or when entry timing creates regulatory gaps. Coordination work is part of typical MedTech engagements.
What about Boston Scientific or 3M suppliers?
Same engagement model as Medtronic suppliers. Tier 2 suppliers face cascading tariff exposure through the Tier 1’s pricing. We run USMCA, Section 232, and IEEPA refund work as needed.
Are you affiliated with Medical Alley Association?
No. We are independent. We attend industry events but maintain no formal affiliation.
Get started
Book a MedTech Section 232 readiness check.